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Project Description: 
This Major Qualifying Project (MQP) was completed to satisfy the requirements of both the 
Biology & Biotechnology and Professional Writing degrees. The purpose was to expand on the 
cellular research done for the Biology & Biotechnology portion by conducting an 
epidemiological study of Emergency Department (ED) Visits for patients with Intellectual and 
Developmental Disabilities (IDD). These two studies worked collaboratively to provide 
groundwork for further studies to evaluate the health and care of individuals with IDD. To 
complete the combined MQP, I conducted the lab work with my team: Renee LeClaire, Lindsey 
Merrill, and Solimar Ramis de Ayreflor Reyes, under the guidance of Professor Natalie Farny. 
Simultaneously, I conducted an epidemiological study evaluating the ED visits of patients with 
IDD under the guidance of Professor Brenton Faber. This MQP worked as an exercise in 
scientific writing and working to provide breadth and depth in knowledge while maintaining 
integrity and understanding of correlation versus causation. 
This full MQP report is a compilation of the work done for both majors. The first chapter 
contains the team-written report done by Renee LeClaire, Lindsey Merrill, and Solimar Ramis de 
Ayreflor Reyes, and myself. The second chapter contains the individually-written 
epidemiological report.  
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Abstract 
The protein FMRP is missing in Fragile X Syndrome (FXS) patients. Stress Granules (SGs) are 
cytoplasmic bodies where mRNAs are stored during cellular stress to inhibit their translation.  
FMRP localizes to SGs and regulates mRNA translation; therefore, we hypothesized that SGs 
may differ in FXS and unaffected cells. We used fluorescence microscopy to quantify SG 
formation in wild type and FXS mouse embryonic fibroblasts and human B lymphocytes. Our 
results suggest altered stress responses may contribute to the pathophysiology of FXS. 
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Introduction 
Cellular Stress Response 
Cellular stress is defined as an introduction to, or a change of, a stimulus that damages the 
structure and function of macromolecules or the cell itself (Poljšak et al. 2012). These stimuli 
can lead to damage of proteins, DNA, other molecules, or cell death (Kultz 2005). To combat 
these stresses, cells have evolved numerous different mechanisms to tackle stressors of various 
levels called cellular stress response (CSR). One of the mechanisms is the formation of stress 
granules. These are created so the cell can survive until the stressor subsides. 
Stress Granules  
A common method of CSR is the formation of stress granules, which have been found across 
yeast, protozoa, and metazoa (Anderson and Kedersha 2009). Stress granules are clusters of 
untranslating messenger ribonucleoproteins (mRNPs) which form from stalled mRNAs (Protter 
and Parker 2016). Stress granules are most often formed after translational initiation is halted due 
to stress-induced phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α). During the 
halted phase, elongating ribosomes are unharmed and simply fall off the stalled polysomes. This 
results in a circularized, polyadenylated mRNA transcript that is still attached to cellular pre-
initiation machinery (Anderson and Kedersha 2009). Figure 1 summarizes the formation and 
breakdown of stress granules within a cell (Dobra et al. 2018).  
Stress granules are believed to sort and degrade mRNA during times of cellular stress and 
recovery. They can also assist with mRNA regulation and stability (Anderson and Kedersha 
2009). In addition, stress granules recruit other molecules which can affect the equilibrium of 
associated molecules. These molecules can also shift the cellular environment into a different 
stage. For example, stress granule recruitment of antiviral proteins during an infection enhances 
innate immune response (Protter and Parker 2016).  
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Figure 1. Assembly of Stress Granules (Dobra et al. 2018) 
Figure 1 displays the formation and breakdown of stress granules in the cytoplasm. The mRNA originates 
in the nucleus, which is outlined in yellow, and enters the cytoplasm. RNPs bind to mRNAs, which 
aggregate in the stress granule so the genetic material is preserved until the stress subsides. Some proteins 
are also present in stress granules. Aggresomes assist in degradation of proteins once the stress granule 
disassembles (Dobra et al. 2018). 
Bisphenols 
Bisphenols are made of two phenols with bridging molecule(s). They are commonly used to 
manufacture plastics and polycarbonates (Konieczna et al. 2015). Bisphenol A (BPA), as shown 
in Figure 2, is a public health concern due to its function as an endocrine disrupting molecule, 
and its analogues are of growing concern as well. BPA is composed of two phenols with a 
bridging carbon that has two methyl groups attached to the carbon (Chen 2002). Steps have been 
taken to eliminate BPA from plastic products, but it is often replaced with its analogues, such as 
bisphenol S or bisphenol F. Despite this removal, BPA is a compound of emerging concern and 
most people in the developed world are exposed to it on a daily basis. 
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Figure 2. Bisphenol A (BPA) molecular structure 
Figure 2 shows the bridging carbon between two phenols. There are also two methyl groups attached to 
the central carbon. 
Bisphenol A (BPA) 
Bisphenol A (2,2-bis(4-hydroxyphenyl)propane, also known as BPA, is an organic synthetic 
chemical that is produced worldwide (Konieczna et al. 2015). BPA was first used in 1891 and in 
the early 1950s it began to appear in industrial and consumer products (Vogel 2009). Since the 
mid-1970s, BPA has been considered a chemical with high-volume production (Vogel 2009). 
Over six billion pounds of BPA are produced each year worldwide and an additional 200 tons of 
the chemical are let out into the atmosphere during its production (Ritter 2011).  
Common products that contain BPA are food containers, baby bottles, toys, water pipes, cell 
phones, laptops, and medical equipment. Humans are exposed to BPA in their everyday lifestyle. 
In fact, the 2003-2004 National Health and Nutrition Examination Survey discovered 92.6% of 
the participants had traces of BPA in their urine (Antonia et al. 2008). BPA concentrations in 
these urine samples ranged from 0.4 µg/L to 149 µg/L and differed between races, household 
income, gender, and age (Antonia et al. 2008). Frequent exposures to BPA can occur through 
inhalation, ingestion, and absorption from dermal exposure. 
In 1993, BPA’s endocrine disruption potential was discovered by endocrinologists at Stanford 
University. They were searching for an endogenous estrogen in yeast but instead came across 
BPA from their polycarbonate flask. The endocrinologists’ research found that BPA was the 
chemical competing with estradiol for estrogen receptors and this was not a product of the yeast 
that they grew in culture. Their published results lead to more research by other scientists on the 
endocrine disruption potential of BPA (Krishnan 1993).  
The human tolerable daily intake, which is defined by the United States Environmental 
Protection Agency as the maximum amount of a substance a human can be exposed to daily 
without adverse effects, of BPA is approximately 50 µg/kg/day. However, adverse effects have 
been detected at lower concentrations of BPA. Low dose effects of BPA have been linked to 
many diseases including birth defects, neurodevelopmental disorders, cardiovascular disease, 
some cancers, and autoimmune disease amongst many more (Rochester 2013). BPA activity 
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frequently resulted in genetic damage, epigenetic changes, endocrine disruption, oxidative stress, 
and/or cell signaling (Rezg et al. 2014). 
Autism Spectrum Disorders and Fragile X Syndrome 
Autism spectrum disorders (ASD) are a class of genetic disorders; ASD affect an individual’s 
social skills, communication, and behavior (Lord et al. 2000). People with ASD may react 
differently to environmental contaminants than people without ASD. One ASD is Fragile X 
Syndrome (FXS), which is caused by extra CGG repeats in the fragile X mental retardation 1 
(FMR1) gene promoter region (Hall and Berry-Kravis 2018). An individual with FXS often has 
varying levels of “intellectual disability, autism, seizures” (Hall and Berry-Kravis 2018). FXS 
affects more males than females since the FMR1 gene is located on the X chromosome 
(Davidovic et al. 2011). Males also have more severe symptoms than females (Hall and Berry-
Kravis 2018). The number of repeats present in FMR1 determines if the individual is unaffected, 
a carrier, or has FXS (Hall and Berry-Kravis 2018). The CGG repeats in the promoter silence the 
FMR1 gene, therefore it cannot translate the fragile X mental retardation protein (FMRP), which 
participates in protein synthesis at the synapse in neurons (Davidovic et al. 2011; Hall and Berry-
Kravis 2018).  
FMRP binds within the coding region of translating mRNA, which slows the elongation rate of 
translating ribosomes (Darnell et. al 2011). Therefore, FMRP represses translation. Also, there is 
evidence that FMRP is present in stress granules and may affect the nucleation of stress granules 
(Anderson and Kedersha 2008). The relationship between FMRP and stress granules is depicted 
in Figure 3. Since FMRP is not present in individuals with FXS, they may have increased 
translation and form stress granules differently than people without FXS. 
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Figure 3. The role of FMRP in stress granule formation (Mazroui et al. 2002) 
Figure 3 displays the relationship between FMRP and stress granule formation. Both FMRP and stress 
granules regulate translation. FMRP binds to translating mRNAs, which hinders the movement of 
ribosomes as they move along the mRNA. Stress granules appear to preserve mRNA during times of 
stress and no translation occurs in stress granules (Anderson and Kedersha 2008; Mazroui et al. 2002). 
In addition, high levels of FMRP might control the repression of mRNPs (Mazroui et al. 2002). 
To learn more about the connection between FMRP and stress granule formation, Gareau et al. 
conducted a study to determine FMRP’s effect on stress granule formation in Drosophila since 
the localization of FMRP in their stress granules is conserved (2013). The study found that 
FMRP is a component amongst many other proteins that are involved in stress granule 
nucleation. Furthermore, Gareau et al. found that FMRP shuttles in and out of stress granules, 
however, it does not alter nor is necessary in Drosophila cells for the formation of stress granules 
(2013). Therefore, cells that do not produce FMRP can still form stress granules because they 
have other proteins involved in the nucleation process. Still, the absence of FMRP alters the 
protein composition of the stress granule (Gareau et al. 2013) and presumably alters the mRNA 
profile as well. It remains unclear what effects if any these changes in stress granules may have 
for individuals with FXS.  
FMR1 knockout mice show an increase in protein synthesis of about 20%, which contributes to 
the effects of FXS on the brain (Udagawa et al. 2013). FMRP binds coding regions of mRNA; in 
FMR1 knockout animals their ribosomes translate excessive proteins from the mRNA because 
they can move freely (Udagawa et al. 2013). In order to make a stress granule, the translating 
ribosomes must detach or run off from the mRNA so the mRNA can become part of the stress 
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granule. Since ribosomes are able to move with more freedom in FMR1 knockout cells than in 
wild type cells, the absence of FMRP may affect the dynamics of stress granule formation. 
Experiments addressing concerns about the effects of daily plastic use on the overall population 
have been conducted, although few have examined the effect on smaller populations, like those 
individuals with FXS. BPA, a component of many plastic products, is known to cause a stress 
response in various cell types (Friend et al. 2018). In this study we examined stress granule 
formation in response to BPA in mouse embryonic fibroblasts (MEF) and human B lymphocytes 
that were either wild type or affected with FXS. We hypothesized there would be a difference in 
the dynamics of stress granule formation between the wild type and FXS affected cells when 
they were exposed to varying concentrations of BPA. Because ribosomes would run off from 
translating polysomes more quickly in the absence of FMRP, we predicted that mRNAs in FXS 
cells would be able to move into stress granules in a shorter amount of time or at lower 
concentrations of environmental stressors. We find that FXS patient lymphoblasts are more 
sensitive to stress granule formation in response to the stressor sodium arsenite, but we see no 
significant difference in stress granule formation in response to BPA. The results suggest that, at 
least in response to some stressors, that FXS-affected cells may be more sensitive to stress, 
which could contribute to the pathogenesis of this disorder.  
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Materials and Methods 
Cell Line Maintenance 
Wild type and FXS affected mouse embryonic fibroblasts and human B lymphocytes were a kind 
gift from Dr. Joel Richter (University of Massachusetts Medical School, Worcester, MA). 
Double stable GFP-G3BP and RFP-Dcp1 U2OS cells (Kedersha et al., 2008) were a generous 
gift from Dr. Nancy Kedersha (Brigham and Women’s Hospital, Boston, MA). The mouse 
embryonic fibroblasts and double stable GFP-G3BP and RFP-Dcp1 U2OS cells were maintained 
in 1x DMEM (Corning Cellgro, Catalog No: 10-013-CV) with 10% fetal bovine serum 
(Equitech-Bio, Inc., Catalog No: 3FBU3132-0500) and 1% penicillin/streptomycin (Lonza, 
Catalog No: 17-602E). The human B lymphocytes were maintained in with 1x RPMI (Sigma 
Life Science, Catalog No: R8758),10% fetal bovine serum and, 1% penicillin/streptomycin.  
Adherent cells, mouse embryonic fibroblasts and double stable GFP-G3BP and RFP-Dcp1 U2OS 
cells, were subcultured approximately every 2 to 3 days. Cell media was removed from the flask 
and discarded into a waste beaker. A Phosphate-buffered Saline (PBS) rinse was completed and 
also discarded into the waste beaker. 1.0 mL of Trypsin (Lonza,Catalog No: CC-5012) was 
added to the flask. The flask was then put in the 37°C incubator for 2-4 minutes to allow the cells 
time to detach from the flask wall. After the flask was removed from the incubator, the flask was 
rinsed with new DMEM media. The new cell containing media was split appropriately into the 
two new flasks; the ratio was between 1:2 and 1:8. More DMEM media was then added to each 
flask to bring the total volume to 14 mL. 
Suspension cells, human B lymphocytes, were also subcultured every 2-3 days. Cell media was 
split into respective ratio and placed in new flasks. Additional mixture of 1x RPMI media with 
10% fetal bovine serum and 1% penicillin/streptomycin was added into each flask to reach a 
total volume of 14 mL.  
B Lymphocyte Cells Pre-Plating 
Coverslips and ultrapure water were autoclaved. The coverslips were then placed one per well on 
the plates and covered with 0.5 mL of polylysine solution (Sigma Life Science , Catalog No: 
P4707). The polylysine coating was left on for an hour in a 37℃ incubator. After one hour 
incubation, the polylysine solution was removed and the coverslips were rinsed with 0.5 mL of 
autoclaved water three times.  
Cell Plating and Pre-Treatment 
The cells were plated in 12 well plates containing coverslips at concentrations ranging from 8 x 
104 - 1.2 x 106 cells per mL. Depending on the cell type, 1 mL of either DMEM or RPMI based 
media was placed into each well before incubating the cells at 37°C for approximately 1-2 days. 
After incubation, 0.5 mL of media was removed from each well and combined with media that 
contained the same cell type and was receiving the same treatment. A 0.1M stock solution of 
BPA was diluted in preconditioned media to achieve the final molar concentration indicated in 
each experimental sample. An untreated sample, the negative control, and an arsenite treated 
sample, the positive control, were also prepared. Figure 4 shows an example of how the 12 well 
plates were utilized for plating and treatment. 0.5 mL of the newly mixed media and reagent 
were added back to each of the appropriate wells and the plate was incubated for one hour at 
37°C. 
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Figure 4. Acute Exposure Assay Treatments 
The treatments for their respective columns are labelled. Neg is negative control, or untreated. Ars is cells 
treated with 100uM of arsenite. 100uM-500uM represent the concentrations of BPA added to each well. 
One of the columns was left empty because only 7 treatments were utilized.  
Cell Fixation  
Fixation was done in order to stop any changes the cells were undergoing (reacting to the 
treatment, dividing, etc). Once the cells were removed from the incubator, and placed in the 
hood, all media and reagent was removed from each of the wells and placed in the discard 
beaker. The wells were rinsed twice with PBS, which was removed and placed in the discard 
beaker. 0.5mL of 4% paraformaldehyde was placed into each well and the plate was placed onto 
the shaker for 10 minutes on medium. After 10 minutes, the plate was brought back into the hood 
and the paraformaldehyde was removed from each well and placed into the hazardous waste 
bottle. 0.5 mL of 1% triton detergent was put into each well and the plate was placed on the 
shaker for an additional 10 minutes. After the second 10 minutes on the shaker, the plate was 
again brought back into the hood, the detergent was removed and placed in the hazardous waste 
bottle. The wells were rinsed with PBS twice, the PBS was removed and placed in the hazardous 
waste bottle each time. PBS was then placed in each well a third time, enough to cover the cover 
slides. The plate was then placed in the refrigerator for storage or brought to the bench for next 
steps. 
Antibody Staining 
The cells were stained in order to see stress granules using fluorescence microscopy. 0.5mL of 
blocking solution, which consisted of 1% PBS and 5% normal horse serum (NHS), was added to 
each well being treated and the plates were left on the shaker for approximately 1 hour. The 
blocking solution was removed and 0.5 mL of a solution containing a ratio of 1uL of the primary 
mouse monoclonal (Abcam, Catalog No: #181150(EPR3986(B)) antibody anti-G3BP to 1mL of 
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blocking solution was added to each well being treated. The plates were placed on the shaker for 
approximately 1 hour. The primary antibody solution was removed and 3 1% PBS washes were 
conducted for 5 minutes each. The plates were put on the shaker during each wash. A solution 
containing a ratio of 1uL of hoechst (Life Technologies, Catalog No: 333342) to, 1uL of 
secondary anti-rabbit (red) antibody (Cell Signaling Technology, Catalog No: 8889S), to 1mL of 
5% NHS + PBS was prepared. 0.5mL of the solution was added to each well being treated and 
the plates were wrapped in tinfoil and placed on the shaker for 1 hour. The solution was removed 
and 3 PBS washes were conducted for 5 minutes each. The plates were put on the shaker during 
each wash. The coverslips with treated cells were mounted with polyvinol mounting media as 
described (Fukui et al., 1987) after completing the antibody staining protocol. 
Data Collection and Statistical Analysis 
The slides were blinded using tape to cover their respective treatment concentration or control 
type. The slides were then analyzed using a fluorescent microscope (Zeiss, Vert.A1, AXIO). The 
microscope lens was set to 20X. Two to three fields were counted, to obtain a total of 250-300 
cells. The percent of stressed cells was calculated by dividing the number of cells that contained 
stress granules by the total number of cells counted on that specific cover slip. The percent of 
nonstress was calculated by dividing the number of cells that did not have any stress granules by 
the total number of cells counted on that cover slip. Each coverslip was counted at least two 
times. The various counts were then averaged.  Experiments were repeated three times unless 
otherwise indicated. Error bars represent the standard error of the mean. Differences between 
samples were analyzed using ANOVA and paired t-tests, as indicated in the figure legends. 
Statistical analyses and data collection were performed using Microsoft Excel.   
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Results 
Verification Trials 
Verification trials using U20S-DS and human B lymphocyte cell lines were conducted to ensure 
that the acute exposure assay would yield cells with visible stress granules and that each group 
member was counting cells, either with or without stress granules, accurately. The cells were 
treated with varying concentrations of BPA for one hour. The cells treated with arsenite served 
as a positive control and untreated cells served as the negative control. Cell fixation ensued 
treatment to allow for scoring of stress granules using a fluorescent microscope.  
 
The first verification trial was performed using U20S-DS cells, which are known to form stress 
granules when exposed to arsenite and BPA (Friend et al. 2018). The data collected in the trial is 
shown in Figure 5. Raw data for the U20S-DS verification trial can be found in Appendix A. 
Figure 5. The average percentage of U20S-DS cells exhibiting stress. These cells were treated for one hour with 
varying concentrations of BPA, 500 uM of arsenite, or left untreated as indicated in the figure. One biological 
replicate was performed. Error bars within the figure represent standard error.  
 
The results were consistent with previous work and showed a dose dependent response as 
anticipated. One biological replicate was completed and counted by two team members. Standard 
error was calculated and shows the variance between the two counts. These results provided 
confidence that the assay would work throughout the experimental period. 
 
A second verification trial was performed using the human B lymphocytes to ensure that the wild 
type (unaffected) and FXS affected cell lines would produce a stress response. Again, untreated 
cells served as a negative control and arsenite treated cells served as a positive control. Figure 6 
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shows the results from the human B lymphocyte verification trial. Raw data for the human B 
lymphocyte trial can be found in Appendix B. 
 
 
Figure 6. The average percentage of human B lymphocytes exhibiting stress. These cells were treated for one hour 
with 500 uM of arsenite or left untreated as indicated in the figure. One biological replicate was performed. Error 
bars within the figure represent standard error.  
 
There is a clear difference between the untreated and arsenite treated B lymphocytes, which 
means these cells are a good candidate for the acute exposure assay. One biological replicate was 
performed but was counted by all four team members. The standard error shows the variance 
between the four counts. 
Mouse Embryonic Fibroblasts 
In order to determine if there was a difference in stress granule formation between the wild type 
(WT) and FMR1 knockout (KO) mouse embryonic fibroblast (MEF) cell lines, an acute exposure 
assay to arsenite and BPA was performed. Identical to the verification trials, an untreated sample 
served as the negative control and an arsenite treated sample was the positive control. The 
fibroblasts were treated with varying concentrations of BPA and the treatment was left on the 
fibroblasts for one hour. The cells were then fixed, stained with anti-G3BP antibody, and scored 
for stress granules using fluorescence microscopy. Images taken using the fluorescent 
microscope can be seen in Figure 7. Panel A shows cells that are not considered to be stressed. 
Panel B shows cells that contain stress granules (the bright red dots). 
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Figure 7. Images taken of mouse embryonic fibroblasts using fluorescence microscopy. (A) shows cells that do not 
have any stress granules and therefore are not considered to be stressed. (B) shows cells that have stress granules 
and there are considered to be stressed 
 
The percentage of cells which had stress granules was calculated and depicted in Figure 8. Raw 
data for the experiment can be found in Appendix C. 
 
 
Figure 8. The average percentage of MEFs exhibiting stress. These cells were treated for one hour with varying 
concentrations of BPA, 500 uM of arsenite, or left untreated as indicated in the figure. Three biological replicate 
were performed. Error bars within the figure represent standard error. ANOVA analysis was completed to find 
statistical significance and is indicated by an asterisk (p < 0.05). 
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After graphing the average percent of stressed cells, there was no dose dependent response as 
previously predicted. For WT cells, the greatest percentage of stress was at the 600 uM 
concentration at 90%. The lowest percentage of stress was at the 400 uM concentration at 14% 
stress. For the KO cells, the highest percentage of stress occurred for the positive control and at 
100 uM (54%) and the lowest percentage of stress occurred at 200 uM (10%). Three biological 
replicates were completed and each replicate was counted by two members for a grand total of 
six counts for each treatment. Standard error shows the variance in biological replicates from 
experiment to experiment. An ANOVA analysis was conducted to find if data from the WT and 
KO cell lines were statistically significant at each concentration. The data was found to be 
statistically significant at the 100 uM, 400 uM, and 600 uM concentration for a p value, p < 0.05.  
Human B Lymphocytes 
In order to determine if there was a difference in stress granule formation between the WT and 
FXS affected human B lymphocyte cell lines, an acute exposure assay to arsenite and BPA was 
performed. An untreated sample served as the negative control and an arsenite treated sample as 
the positive control. The lymphocytes were treated with varying concentrations of BPA and the 
treatment was left on the lymphocytes for one hour. The cells were then fixed, antibody stained, 
and scored for stress granules using a fluorescent microscope. Images of the cells taken by the 
fluorescent microscope can be seen in Figure 9.  
 
Figure 9. Images taken of human B lymphocytes using fluorescence microscopy. (A) shows cells that do not have 
any stress granules and therefore are not considered to be stressed. (B) shows cells that have stress granules and 
there are considered to be stressed 
 
The data obtained from this experiment is shown in Figure 10. Raw data for the experiment can 
be found in Appendix D. 
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Figure 10. The average percentage of human B lymphocytes exhibiting stress. These cells were treated for one hour 
with varying concentrations of BPA, 500 uM of arsenite, or left untreated as indicated in the figure.  Three 
biological replicate were performed. Error bars within the figure represent standard error. ANOVA analysis was 
completed to find statistical significance and is indicated by an asterisk (p < 0.05). 
 
 
As seen in Figure 10, the data mimics the dose dependent response as predicted and seen in the 
U20S-DS cell line. There was an increase in percent of stressed cells as the concentration of 
BPA exposure increased. Three biological replicates were completed and each replicate was 
counted by two members for a grand total of six counts for each treatment. Standard error shows 
the variance in these counts. An ANOVA analysis was conducted to find if data from the 
unaffected and affected cell lines were statistically significant at each concentration. The data 
was found to be statistically significant for our positive control, Arsenite, only with a p value 
where p < 0.05.  
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Discussion 
We noted a significant increase in stress granule formation in FXS affected B lymphocytes in 
response to arsenite. The FXS affected cells showed increased stress granule formation, 
however, this difference was not statistically significant. The results from the FXS affected 
mouse fibroblast cells had some statistical significance, but no conclusive findings. Further 
research is necessary to determine if there is a statistical significance in stress granule formation 
between FXS affected and unaffected cells. 
Reasons for Discrepancies in Data 
There were no trends seen in the mouse embryonic fibroblast data, which could be the result of 
many factors. These cells were the same type but they were not littermate and passage matched: 
they were not from mice from the same litter, nor were they at the same passage number and 
therefore they did not follow the same growth trends. These variable growth trends led to the 
unaffected cells undergoing more passages than the affected cells. This can affect their base level 
of stress, and therefore, alter the results after the treatment. If one group of cells is more stressed 
when plating one day over another, this would yield different results. Since we averaged all of 
the counts we did for each biological replicate, the day-to-day differences could have altered the 
overall result. 
Additionally, some technical errors could have affected the results we obtained. While scoring 
the embryonic fibroblast cells, the microscope in Goddard Hall broke and required repair, so in 
order to keep the momentum of the project going, we used a microscope owned by the 
Biomedical Engineering Department in Salisbury Labs. This scope worked by taking photos of 
the cells and counting them on a computer screen, rather than looking through the eyepiece of 
the microscope to count. This change in methods may have altered our results.  
Once the cells were mounted on the slides, the team took precautions so the slides would not be 
exposed to light for an extended amount of time, however, they still may have faded which 
would cause the fluorescently stained stress granules to appear dimmer, making the counter less 
likely to see them or count the cell as stressed. 
Many of these problems were ameliorated when the team transitioned over to the B lymphocytes. 
The cells used for the B lymphocyte trials were from brothers: one has Fragile X Syndrome and 
one does not. This means that these cells were better matched, and they grew at about the same 
rate so they had about the same number of passages. However, discrepancies are seen between 
the verification trial and the results with these cells. The level of stress seen in the arsenite 
treated (positive control) is much higher, and not significantly different between cell types, for 
the verification trial. We predict that this is because the way this verification trial was set up led 
to subconscious bias to alter the results. The verification trial was not blinded. Additionally, we 
knew that the slides were either a positive or negative control, which could cause us to count 
cells as stressed when in a blinded count we would evaluate the cell more closely before 
counting it as stressed or unstressed. 
Future Experimentation 
This project grew out of previous experimentation evaluating cellular stress response to various 
concentrations of BPA. Therefore, we have some suggestions for future experiments with FXS 
affected cells and BPA. We recommend the following: 
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1. Redo the experiment with the mouse fibroblast cells, but remove some of the issues that 
we came across. Use matched cell lines if they are available, and try to be more 
consistent with passaging so the cells undergo the same number of passages. Use the 
same microscope throughout the experiment. Continue with performing biological 
replications in triplicate and perform at least two technical replicates to account for 
personal error. 
2. Redo the experiment with B lymphocytes. These cells performed well for this team but 
assuring that the results are reproducible will add to the validity of the study. If this is the 
case, treat the cells with BPF or BPA and BPF to see if other bisphenols, or a 
combination of bisphenols, affects stress response. 
3. Another worthwhile change would be to see how affected and wildtype cells react to 
incubation with arsenite or BPA at different incubation times. Stress granules are 
dynamic, and by incubating at different times there are more snapshots of the stress 
response available that would give information about reaction time to the compounds that 
could vary between affected and unaffected cells. 
Impact on Patients with Fragile X Syndrome 
If the results for these experiments are reproducible, they can be used to draw conclusions on 
how environmental contaminants may affect patients with FXS. For instance, if FXS patients are 
more sensitive to environmental contaminants, they may form stress granules at lower levels of 
exposure. If FXS patients’ cells have an increased number of stress granules, the cells are not 
able to synthesize protein because translation is inhibited in stress granules. Therefore, the cell 
will eventually die, or work improperly, because it is not able to produce proteins. Chronic cell 
stress can cause ischemia, neurological diseases, and cancer (Reineke and Neilson, 2019).  
Once information as to whether or not the differences in cellular stress response translate to 
differences at the patient level, further research can be done to see if the effects seen in patients 
with FXS are the same in patients with other ASD and intellectual and developmental 
disabilities.  
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Chapter Two:  
Disease and the Human 
Experience:  
ED Visits for Intellectually and 
Developmentally Disabled 
Patients Versus National 
Averages 
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Abstract 
Research has found an altered stress response in cells with Fragile X Syndrome. Literature has 
shown that patients with intellectual and developmental disabilities (IDD) experience an 
increased rate of ED admissions. I hypothesized that IDD individuals would have different trends 
in their ED diagnoses due to the differing stress response. I conducted epidemiological research 
of a population of IDD individuals' ED visits compared to national averages and the infection 
and injury rates were found to be elevated. 
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Introduction 
Although plastics and BPA have been shown to be present in different levels for those with 
certain intellectual and developmental disabilities (IDD), there is little verifiable research about 
how toxicity in general affects people with IDD. The biology portion of this MQP showed an 
increase in stress granule formation in human B lymphocytes affected with Fragile X Syndrome 
present with more stress granules when exposed to arsenite and BPA, two known toxins. 
Children with IDD have an increased risk of exposure to toxins like lead and mercury due to 
certain tendencies in behavior and communication. In addition, certain dietary restrictions like 
galactosemia may increase the effects of lead exposure for the child. If the child is exposed to 
toxins and shows symptoms they may present themselves similarly to the IDD and may be 
overlooked (Graft et. al 2006). However, there are many more problematic toxins than just 
mercury and lead.  
Stress granules also form as a protective measure against stressors other than toxins, such as 
fever. People with IDD are more likely to have certain health problems with could lead cellular 
stress and to ED visits. The question persists regarding how this difference in stress granule 
formation may affect individuals at the patient level and contribute to differences in Emergency 
Department (ED) visits between people with IDD and the general public.  
This study will analyze the ED visits of patients with IDD at Canton-Potsdam Hospital (CPH) 
and address possible reasons for the trends seen in this study population. 
Epidemiology Studies 
Epidemiology is defined by the Boston Medical Journal as “is the study of how often diseases 
occur in different groups of people and why”. Studies like these give insight as to how certain 
groups are affected by diseases or conditions and the severity and frequency of their cases. In 
small scale studies where only one hospital is the source of patient data, the answer to why the 
differences (or lack thereof) are the way they are may not be evident or show a significant 
enough correlation to draw conclusions. Studies that show a group’s health trends in different 
locations, under different conditions, and at different hospitals allow for conclusions to be drawn 
between the group and their health trends. 
Health Among People with Intellectual and Developmental Disabilities  
People with IDD have an increased risk of certain conditions, notably: “motor deficits, epilepsy, 
allergies, otitis media, gastroesophageal reflux disease (GERD), dysmenorrhea, sleep 
disturbances, seizure disorders, mental illness, vision and hearing impairments, oral health 
problems, and constipation” (May, et. al, 2010). Constipation affects 75% of people with IDD, 
GERD affects as many as 48%, 25% experience otitis media (middle ear infection), and 35-90% 
have sleep disturbances. These conditions can directly lead to visits to the ED, but also a 
person’s reaction to the condition may also cause injury and send the person to the hospital. May 
et. al (2010) discussed that otitis media can lead to self-injury. This can escalate the problem to 
require an ED visit. 
People with IDD use the ED 1.56-2.68x more than the general population according to reports 
from Canada and England (Hosking, et. al, 2017 & Lunsky et. al, 2012). These prevalence 
numbers were not found in published literature for the United States. One study conducted in the 
United States looked at the ED trends of patients with IDD and found that “intellectually 
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disabled adults were more likely (P < .05) than the convenience sample of the general adult ED 
population to have ICD-9 diagnoses among infectious/parasitic, nervous system/sense organs, 
and respiratory disorders, less likely among neoplastic, mental, circulatory, musculoskeletal, and 
injury/poisoning disorders” (Venkat et. al, 2011).  The study done by Venkat et. al was 
conducted with patients from one residential care setting. For this MQP one hospital was used, 
and the living situation for the patients was not provided.     
Objectives 
This study will aim to evaluate the most common reasons people with IDD visit the Emergency 
Department by looking at a sample study population, their primary diagnoses in the Emergency 
Department, and the possible reasons this is the case. I predict that there will be differences in 
the diagnoses patients with IDD receive at CPH compared to national averages. 
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Materials and Methods 
Obtaining Patient Data 
Patient data was obtained after IRB approval from Worcester Polytechnic Institute (WPI) and 
Canton-Potsdam Hospital. It was pre-screened for relevance and all identifiable information was 
omitted prior to the release of it on the WPI password secure serve.  
Included and Excluded Data 
The patients that were included in the study data set were all diagnosed with intellectual and 
developmental disabilities, though the exact diagnosis was not provided, as it would cause the 
data to be more identifiable due to the small community this hospital serves.  
Primary, secondary, and tertiary diagnoses for each emergency department visit were given in 
the data set; however, the primary diagnoses were the only one used, unless the primary 
diagnosis was a note and not a diagnosis, in which case the secondary diagnosis was used 
instead.  
Based on these qualifications, a total of 82 patients and 400 individual visits to the Emergency 
Department of Canton-Potsdam Hospital (between October 2000 and January 2019). 
National averages were obtained from National Hospital Ambulatory Medical Care Survey’s 
Emergency Department Summary Tables. Years 2008-2015 were averaged in order to give a 
view of national averages over the eight-year period. These years were chosen because 2015 was 
the most recent data available from the CDC when this project was conducted and 2008 was the 
latest available that was provided in the same manner as previous years.  
Data Mining 
ICD-9 and ICD-10 
The data set had diagnoses that were categorized by ICD-9 and ICD-10 coding. Since the 
national averages were done with ICD-9 information, all ICD-10 diagnoses in the study set were 
converted to ICD-9. This was done by converting groups (i.e. diseases of the respiratory system 
was a category in ICD-9 and ICD-10) but also individuals by searching the ICD-9 code on online 
databases when the categories were not as clearly transferable (i.e. ICD-9 paired “endocrine, 
nutritional and metabolic diseases, and immunity disorders” and “diseases of the blood and blood 
forming organs” where ICD-10 paired “diseases of the blood and blood forming organs and 
certain disorders involving the immune system” and “endocrine, nutritional, and metabolic 
diseases”).  
After this conversion was done, all data was used, evaluated, and displayed in ICD-9 coding. 
Categorization 
The categories used were predetermined ICD-9 codes. They include the following: 
• Infectious and parasitic diseases 
• Neoplasms 
• Endocrine, nutritional and metabolic diseases, and immunity disorders 
• Diseases of the blood and blood forming organs 
• Mental disorders 
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• Diseases of the nervous system 
• Diseases of the sense organs 
• Diseases of the circulatory system 
• Diseases of the respiratory system 
• Diseases of the digestive system 
• Diseases of the genitourinary system 
• Diseases of the skin and subcutaneous tissue 
• Diseases of the musculoskeletal system and connective tissue 
• Symptoms, signs and ill-defined conditions 
• Injury and poisoning* 
• Supplementary classifications 
*Further breakdown was available for injury and poisoning:   
• Fractures 
• Sprains and strains 
• Intracranial injury 
• Open wounds 
• Superficial injury 
• Contusion with intact skin surface 
• Foreign bodies 
• Burns 
• Trauma complications and unspecified injuries 
• Poisoning and toxic effects 
• Surgical and medical complications 
• Other 
Data Analysis 
Each encounter was used as an individual data point in the data analysis. If one patient had six 
visits on different days, each of those visits counted toward the associated diagnosis. However, if 
there were multiple entries in the system for one visit, they were only counted once.  
Due to the nature of this experiment, statistical analysis could not be done. This is because the 
study data only came from one group, and this group consisted of 82 people, so a standard 
deviation and standard error could not be calculated. 
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Figure 11. Visual Representation of the Methods of the Epidemiological Study 
  
IRB approval by WPI and CPH
Anonymous data gathered from 
CPH
Organization of data by primary 
diagnosis
Transfer of ICD-10 diagnoses to 
ICD-9
Comparison and analysis of 
differences in visits by patients 
with IDD and national averages
 33 
Results and Conclusions 
Table 1. A comparison of the epidemiological findings and national averages provided by 
National Hospital Ambulatory Medical Care Survey (NHAMCS, 2008-2015) 
Major Disease Category (ICD-9) Epidemiological Findings Average 2008-2015
Infectious and parasitic diseases 1.0% 3.0%
Neoplasms 0.0% 0.2%
Endocrine, nutritional, metabolic diseases, and immunity disorders 1.3% 1.6%
Mental disorders 0.8% 3.7%
Diseases of the nervous system and sense organs 5.0% 4.9%
Diseases of the circulatory system 1.5% 3.5%
Diseases of the respiratory system 13.3% 10.4%
Diseases of the digestive system 4.5% 6.0%
Diseases of the genitourinary system 5.8% 5.2%
Diseases of the skin and subcutaneous tissue 4.3% 3.9%
Diseases of the musculoskeletal system and connective tissue 3.0% 6.8%
Symptoms, signs and ill defined conditions 16.5% 22.3%
Injury and poisoning 39.0% 21.6%
Supplementary classifications 3.8% 2.6%  
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Figure 12. A comparison of the epidemiological findings and national averages provided by 
National Hospital Ambulatory Medical Care Survey (NHAMCS, 2008-2015) 
This Figure shows the comparison between the study population and national averages for all main ICD-9 
categories 
 
The cumulative averages for five years of data (2008-2015) were compared to the 
epidemiological findings from the visits of patients with IDD at the ED.  
Among the IDD population evaluated, injury and poisoning (39%) were the most common cause 
for the ED visits. In the national averages, “symptoms, signs, and ill-defined conditions” (22.3%) 
were most prevalent with injury and poisoning cases (21.6%) making up the second most 
diagnoses. 
There was a further breakdown available in the national average tables for injury and poisoning 
visits. Breakdowns for other ICD-9 categories was not available from the national averages so 
they will not be discussed in this report. 
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 35 
Table 2. Breakdown of the injury and poisoning diagnoses in the study findings and National 
Hospital Ambulatory Medical Care Survey averages (NHAMCS, 2008-2015) 
Injuries and Poisoning Subcategories Study Population Average 2008-2015
Fractures (800-829) 4.3% 2.8%
Sprains and Strains (840-848) 6.5% 4.4%
Intracrainal injury (850-854) 2.0% 0.4%
Open wounds (870-897) 8.5% 4.0%
Superficial injury (910-919) 2.5% 1.2%
Contusion with intact skin surface (920-924) 9.3% 3.3%
Foreign bodies (930-939) 1.0% 0.4%
Burns (940-949) 0.3% 0.4%
Trauma complications and unspecified injuries (958-959) 2.8% 2.0%
Poisioning and toxic effects (960-989) 0.3% 0.7%
Surgical and medical complications (996-999) 0.8% 0.4%
Other 1.0% 1.3%  
 
 
 
Figure 13. Breakdown of the injury and poisoning diagnoses in the study findings and National 
Hospital Ambulatory Medical Care Survey averages (NHAMCS, 2008-2015) 
This Figure shows the comparison between the study population and national averages for the injury and 
poisoning category. 
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The breakdown of injury and poisoning diagnoses showed that contusions (9.3%) and open 
wounds (8.5%) were the most common injury and poisoning diagnoses for the IDD population. 
Strains and sprains (4.4%) were the most common nationally. It is important to note that these 
percentages are compared to all cases recorded (n=400 for the study population), not just in the 
injury and poisoning subcategory.  
Poisoning and toxic effects (0.3%) caused the lowest number of cases in the IDD population, tied 
with burns. This is a little under half of the proportion of cases caused by poisoning and toxic 
effects in the general population (0.7%).  
Overall, the prediction that IDD individuals may have significantly different diagnoses in the ED 
cases than the national averages was supported. However, due to the small sample size, more 
research needs to be done in order to draw conclusions for people with IDD as a whole. 
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Discussion 
Although this study is small, there are some points that can be drawn from it especially for 
Canton-Potsdam Hospital. This study supports the general idea that people with IDD have 
different medical needs and use the ED for different things. These trends, if studied more, can be 
used to serve this population more efficiently.  
Limitations 
There are many limitations for a study this size. For one, the population this study worked off of 
was only 82 people with 400 total emergency department visits. This is not large enough to draw 
true conclusions, but it serves as a pilot study to look at trends and form goals for further 
research. 
Additionally, there are factors that could contribute the chief complaint of the visit that is not 
necessarily tied to the patient’s IDD but rather their living environment, elements of the climate, 
and the type of area (rural, suburban, urban) they live in. A larger population would allow for 
more conclusions to be drawn and for statistical analysis to be done to find out if the differences 
seen in ED visit trends are caused by IDD.  
Causes for Differences in Trends 
The trends seen in this study are in contrast to those seen in Venket et. al. The study done by 
Venket et. al found significantly less visits attributed to injury and poisonings. However, that 
study was done with people who were in residential care facilities, whereas this study was not 
limited to people from certain living situations and most likely was composed of individuals 
from residential care facilities and those who lived at home.  
The variety in diagnoses for IDD individuals compared to the national averages could stem from 
a few things. Since the majority of injury and poisoning visits were caused by physical trauma 
related conditions (35%) these individuals may be more prone to these conditions based on their 
disability. May et. al (2010) notes that motor deficits, epilepsy, and seizure disorders are more 
prevalent in individuals with IDD. All of these conditions can lead to physical trauma. 
Additionally, if they live in a group home or under the supervision of a trained caretaker, they 
may be less likely to be exposed to things that may cause harm, like poisonous chemicals or 
alcohol which could lead to toxicity. 
Further research  
This study showed that there were differences in the reasons individuals with IDD came to the 
ED at CPH compared to national averages. Therefore, it is valuable to expand this study to see if 
these trends carry over with larger populations of people with IDD. Additionally, all of these 
visits occurred at Canton-Potsdam Hospital, a hospital in a St. Lawrence Country in Upstate New 
York. This is a rural location so this may influence the cases they see. Obtaining data from 
suburban, urban, and more rural hospitals from all states would add to the data pool and possibly 
allow for more insight into the trends of patients with IDD without the influence of location. 
Additionally, if the population size allows for the breakdown of the patient’s IDD diagnosis 
without causing issues with anonymity, research into individuals with specific diagnoses: Down 
Syndrome, Fragile X Syndrome, etc. would add to the specificity of the research and provide 
additional insights.  
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The research done here can help Canton-Potsdam Hospital improve the care of their patients with 
IDD; further research could guide healthcare providers in allocating resources and improving 
care in the ED for patients with IDD in all hospitals. 
Connection to Science Writing 
This project was an epidemiological study connecting disease and the human experience. 
Understanding the multi-faceted nature of health is essential for medical and scientific 
communication that benefits patients and the healthcare system. Additionally, science writing is 
fact-based, so science writers need to understand the difference between correlation and 
causation. This study only showed correlations because of the small sample of patients, so many 
different reasons for this were discussed, and causation was not drawn from the study. 
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Appendices 
Appendix A - Raw Data for U20S-DS cell line verification trial 
 
Treatment Stressed 
Not 
Stressed 
Tota
l 
% Stressed 
Neg 
1 258 259 0.39 
22 252 274 8.03 
7 258 265 2.64 
14 255 269 5.20 
Ars 
254 1 255 99.61 
303 0 303 100.00 
420 44 464 90.52 
268 1 269 99.63 
100 uM 
7 262 269 2.60 
18 257 275 6.55 
1 271 272 0.37 
18 274 292 6.16 
200 uM 
7 246 253 2.77 
16 302 318 5.03 
3 251 254 1.18 
16 248 264 6.06 
300 uM 
143 133 276 51.81 
140 137 277 50.54 
142 144 286 49.65 
112 146 258 43.41 
400 uM 263 5 268 98.13 
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58 329 387 14.99 
249 10 259 96.14 
255 89 344 74.13 
500 uM 
249 4 253 98.42 
268 5 273 98.17 
255 14 269 94.80 
291 113 404 72.03 
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Appendix B - Raw Data for Human B Lymphocyte verification trial 
 
Unaffected  Affected 
Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed 
 Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed 
Neg 
4 177 181 2.21  
Neg 
14 191 205 6.83 
3 104 107 2.80  8 139 147 5.44 
3 119 122 2.46  11 127 138 7.97 
44 169 213 20.66  5 168 173 2.89 
Ars 
150 13 163 92.02  
Ars 
189 24 213 88.73 
104 12 116 89.66  78 35 113 69.03 
113 9 122 92.62  123 22 145 84.83 
116 47 163 71.17  164 44 208 78.85 
  
 44 
Appendix C - Raw Data for MEF cell line acute exposure assay 
 
Wildtype  Knockout 
Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed  
Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed 
Neg 
1 255 256 0.39  
Neg 
38 96 134 28.36 
6 232 238 2.52  41 69 110 37.27 
71 116 187 37.97  7 243 250 2.80 
89 116 205 43.41  11 247 258 4.26 
9 250 259 3.47  6 216 222 2.70 
11 260 271 4.06  16 198 214 7.48 
Ars 
20 241 261 7.66  
Ars 
138 80 218 63.30 
24 235 259 9.27  117 116 233 50.21 
248 18 266 93.23  89 108 197 45.18 
17 215 232 7.33  118 77 195 60.51 
165 126 291 56.70  145 108 253 57.31 
218 81 299 72.91  130 124 254 51.18 
100 uM 
61 155 216 28.24  
100 uM 
60 153 213 28.17 
62 152 214 28.97  64 131 195 32.82 
17 245 262 6.49  159 76 235 67.66 
9 256 265 3.40  140 79 219 63.93 
200 uM 
148 133 281 52.67  
200 uM 
20 221 241 8.30 
163 173 336 48.51  43 170 213 20.19 
14 245 259 5.41  16 248 264 6.06 
27 197 224 12.05  11 205 216 5.09 
300 uM 
225 29 254 88.58  
300 uM 
30 226 256 11.72 
221 30 251 88.05  40 223 263 15.21 
46 204 250 18.40  71 159 230 30.87 
 45 
15 253 268 5.60  112 135 247 45.34 
109 139 248 43.95  95 137 232 40.95 
97 177 274 35.40  70 129 199 35.18 
400 uM 
105 172 277 37.91  
400 uM 
81 89 170 47.65 
9 243 252 3.57  114 66 180 63.33 
40 253 293 13.65  47 195 242 19.42 
72 218 290 24.83  14 215 229 6.11 
4 276 280 1.43  199 37 236 84.32 
7 209 216 3.24  242 10 252 96.03 
500 uM 
237 48 285 83.16  
500 uM 
227 39 266 85.34 
213 47 260 81.92  233 24 257 90.66 
48 147 195 24.62  51 207 258 19.77 
47 147 194 24.23  27 257 284 9.51 
157 102 259 60.62  95 137 232 40.95 
149 87 236 63.14  6 262 268 2.24 
600 uM 
242 37 279 86.74  
600 uM 
144 123 267 53.93 
236 17 253 93.28  115 145 260 44.23 
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Appendix D - Raw Data for Human B Lymphocyte cell line acute exposure assay 
 
Unaffected  Affected 
Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed 
 Treatment Stressed 
Not 
Stressed 
Total 
Percent 
Stressed 
Neg 
7 111 118 5.93  
Neg 
7 126 133 5.26 
24 115 139 17.27  19 139 158 12.03 
12 166 178 6.74  30 183 213 14.08 
6 145 151 3.97  3 117 120 2.50 
12 186 198 6.06  15 198 213 7.04 
9 88 97 9.28  22 133 155 14.19 
Ars 
127 126 253 50.20  
Ars 
165 52 217 76.04 
81 62 143 56.64  100 78 178 56.18 
102 156 258 39.53  201 78 279 72.04 
93 124 217 42.86  142 135 277 51.26 
108 57 165 65.45  114 87 201 56.72 
9 91 100 9.00  102 7 109 93.58 
100 
26 232 258 10.08  
100 
97 115 212 45.75 
14 140 154 9.09  90 158 248 36.29 
11 116 127 8.66  13 109 122 10.66 
13 97 110 11.82  7 102 109 6.42 
21 171 192 10.94  27 208 235 11.49 
1 154 155 0.65  14 139 153 9.15 
200 
23 118 141 16.31  
200 
31 122 153 20.26 
26 148 174 14.94  35 112 147 23.81 
2 258 260 0.77  16 171 187 8.56 
35 201 236 14.83  34 129 163 20.86 
63 59 122 51.64  77 121 198 38.89 
 47 
32 69 101 31.68  44 72 116 37.93 
300 
8 137 145 5.52  
300 
37 109 146 25.34 
0 140 140 0.00  25 165 190 13.16 
12 204 216 5.56  41 114 155 26.45 
97 125 222 43.69  39 98 137 28.47 
129 99 228 56.58  107 109 216 49.54 
51 109 160 31.88  48 135 183 26.23 
400 
24 176 200 12.00  
400 
149 64 213 69.95 
11 154 165 6.67  105 75 180 58.33 
78 196 274 28.47  43 219 262 16.41 
95 171 266 35.71  20 95 115 17.39 
41 79 120 34.17  50 63 113 44.25 
69 40 109 63.30  96 36 132 72.73 
500 
103 49 152 67.76  
500 
98 22 120 81.67 
72 71 143 50.35  148 46 194 76.29 
24 67 91 26.37  22 109 131 16.79 
74 13 87 85.06  31 80 111 27.93 
47 154 201 23.38  40 74 114 35.09 
37 119 156 23.72  105 64 169 62.13 
 
 
 
 
